| Micro-channel |
 |
|
|
|
|
|
| |
| The original pharmaceutical industry big shuffle or price rises to stop the terminal drug to be difficult to follow the rise |
| |
| Author：中国铭铉 企划部 Release Time：2017-9-6 15:54:14 Number Browse：814 |
| |
Medical network - on September 6, has 10 ministries and commissions such as environmental protection, development and reform commission (NDRC), the joint Beijing, hebei and other 6 provinces (city) government issued the beijing-tianjin-hebei in and around 2017 ~ 2018 season atmospheric pollution comprehensive treatment crucial action plan "(hereinafter referred to as" the plan "), with particular emphasis on: the manufacture of active pharmaceutical ingredients involved in pharmaceutical enterprise, if in violation of the emission process principle, the implementation of production. The personage inside course of study, said: "many API companies are large polluters, so real, is bound to shut down a number of factories, downstream may face from time to time out of stock outages, but I can't follow terminal medicine prices."
The API industry or the big shuffle
It is reported, at the end of last year, shiyao, north China pharmaceutical production enterprise for environmental protection do not API standards were ordered to stop production and losses, according to the north China pharmaceutical bulletin shows that due to production net loss of 54.93 million yuan.
According to the plan, from July 1, 2017, we will strictly implement the standards of petrochemical industry emission standards and promote the comprehensive treatment of VOCs (volatile organic compounds) in industries such as pharmaceuticals. Before the end of October 2017, the local governments will basically complete the renovation work, and the enterprises that have not completed the reform will be implemented in accordance with the law, and will be included in the winter peak production plan. Before the end of December 2017, the work of emission permits for the manufacturing of raw materials will be completed.
In the case of excessive emission enterprises, the "plan" punishment measures can be very "expensive", namely, the penalty can be corrected immediately, and the enterprise shall be ordered to rectify the problem immediately. Unable to complete the rectification immediately, implement the shutdown; The "daily punishment" shall be carried out in accordance with the law, which involves the people's livelihood.
"Recently, the raw material pharmaceutical factory inspection failed to get the GMP certificate, resulting in the supply of conventional medicine and the dealers to hold up the goods. As the New Deal is implemented, a batch of pharmaceutical companies will be expected to shut down. One industry observer told reporters.
It is understood that since last year, the production of their production is concentrated in the active pharmaceutical ingredients and Chinese medicine yinpian production enterprises both environmental protection and quality problem areas, and under the background of environmental policy continuously upgrade, for pharmaceutical industry in our country or in the short term will have big reshuffle.
"Environmental threat, or reversed transmission enterprises close down backward production facilities, or to large-scale relocation, but environmental upgrades is not can be done overnight, so the process will force many small and medium-sized pharmaceutical companies, and environmental protection measures in place of the leading enterprises in market share could rise further." The observer said.
Downstream companies dare not raise prices at will
In the long run, environmental policy is beneficial to the transformation and upgrading of the pharmaceutical industry, but in the short term, the impact of price rises and broken supply can be brought. Analysts believe that apis are a feature is a pair of many, may then several API companies to underwrite much of the country hundreds of drug firms supply of raw materials, it is also a raw material approval and other birth defects caused by less, so once the shut down some drug companies, might bring great influence on market supply and price fluctuations.
Will the terminal drug "rise and rise", triggering a price rise? The observer says consumers need not worry too much. "The price of raw materials for downstream pharmaceutical companies should be priced at their own price." Behind that, price regulation is at work. "Drug prices after let go, I dare not pricing, drug companies and for monitoring is very strict, some drug companies would rather raw material when you temporarily not production, did not want to risk the risk on the interview to rise in price easily, especially for market share proportion is not high, is not a product of the companies' cash cow ', more won't rise in price easily."
|
| |
Previous article：There were 2,873 new drug catalogs for medical insurance reimbursement
Next article：5. Overview of the semi-annual report of a-share listed pharmaceutical manufacturing enterprises in 2017
|
| |
|
|
